SEO URLwww.firestrike.ai/deals/amicus-therapeutics-biomarin-acquisition-2026-3
acquisitionAnnounced · Jan 12, 2026PharmaceuticalsSource · CredibleArticle · Factual
BioMarin acquires Amicus Therapeutics
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$4.8B
Target
Amicus Therapeutics
NASDAQ: FOLD · Princeton, New Jersey
Acquirer
BioMarin
Full Acquisition
Status
Pending
BioMarin agreed to acquire Amicus Therapeutics. Reported deal value: $4.8B. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: Princeton, New Jersey, United States.
This page summarizes publicly available information about the transaction as of 2026-01-12. Figures and status may change as filings and press coverage update.
Published Category Biotech Latest News BioMarin Pharmaceutical has entered into a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction valued at approximately $4.8 billion
Deal timeline
Announced
Jan 12, 2026 · thehealthcaretechnologyreport.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals with a reported deal value of $4.8B. Figures and status may change as sources update.
Sources: thehealthcaretechnologyreport.com · Primary article · FireStrike proprietary index